A top analyst spotlights a wave of biotech startups looking to catapult onto Nasdaq — or get bought out
There should be no shortage of biotech companies looking to file an IPO — or execute a buyout deal — in 2020 and 2021.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,100+ biopharma pros reading Endpoints daily — and it's free.